MassBioDrive header

Spring 2022 Cohort

Artificial Axon Labs Inc.

Based in Massachusetts

Anna Jagielska, Ph.D., President, CEO, CSO, & Co-Founder
Kavin Kowsari, Vice-President, CTO, & Co-Founder

Artificial Axon Labs is developing a transformational drug discovery platform to discover medicines for neurodegenerative diseases. Our technology, developed by the

company founders at MIT, combines novel biocompatible materials, state-of-the-art 3D printing of axon mimics (Artificial Axons), and patient-derived human cells to generate first-in-class remyelinating drugs for Multiple Sclerosis.

Atorvia Health Technologies

Based in Canada

Jane Lapon, CEO
David Allinson, CFO & Head of Business Development
Nermeen Varawalla MD, Chair Clinical Advisory Group
Steven C. Borkan MD, Associate Professor, Boston Medical Centre

Atorvia’s purpose is to transform outcomes for patients with severe medical conditions.  Our initial focus is acute kidney injury (AKI), a devastating condition which affects millions worldwide yet still lacks effective therapy.  To address this crisis, we are developing a kidney-targeted peptide that prevents regulated cell death and kidney failure.

Modulari-T Biosciences

Based in Canada

David Cotnoir-White, Ph.D., CEO & Co-Founder
Étienne Gagnon, Ph.D., CSO & Co-Founder

Modulari-T is a preclinical stage immunotherapy startup developing a novel platform, the MARC, to reprogram immune cells for oncology and beyond. Our MARC technology is twice as potent as CAR-T while reducing side-effects ten-fold which will enable adoptive cell therapy to break-in to new indications in autoimmunity and regenerative medicine.

PhenoTarget Biosciences, Inc.

Based in California

Shoutian Zhu, Ph.D., CEO
Wenshe Liu, Ph.D., CSO
James Schaeffer, Ph.D., CBO

PhenoTarget Biosciences, Inc. is a biotech startup focused on the discovery and development of first-in-class therapies for unmet medical needs including oncology, fibrosis, cardiovascular diseases and infectious diseases. We are modality agnostic that our pipeline and technology platforms span small molecules to functionalized peptides and next generation cell therapies., Inc.

Based in Massachusetts

Martin Williams, CEO & Founder is an early-stage synthetic biology company focused on the discovery, development and future commercialization of precision therapeutics using its proprietary Linear DNA and Circular RNA technology platforms. aims to deliver novel and effective therapeutics and vaccines enabling precise corrective and preventive treatments for patients worldwide.